

Zoono Group Limited (ASX:ZNO)

Results Presentation

Full year ended 30 June 2020



Paul Hyslop – CEO/Managing Director



Lew MacKinnon – Chief Operating Officer



Paul Ravlich – Chief Financial Officer

CONTENTS





- Group Highlights
- 2 Financial Information
- 3 Strategy & Growth

Appendices

Financial Reconciliation to Statutory Results

Zoono Group Limited


#01

Group Highlights











1.1 Business Highlights – 30 June 2020



Extremely Strong FY20 financial performance & high operating margins achieved & low overheads

EBITDA

Revenue (Group)

 Total Revenue: NZ\$38.3m (FY19: NZD\$1.8m) + NZ\$36.5m improvement +2,056.8% increase vs. FY19

EBITDA (Group)

- Operating EBITDA: NZ\$20.6m (FY:19 NZ\$(2.4m)) + NZ\$23.0m improvement +944.5% increase vs. FY19
- Inventory: NZ\$13.2m increase of NZ\$12.7m over FY19

Consolidated Profit & Loss (NZ\$m)	Actual FY20	Actual FY19	FY20 vs. FY19 %
Revenue			
Revenue - Total	38.3	1.8	2,056.8%
Gross Profit	28.3	0.8	3,369.3%
Margin (%)	73.9%	46.0%	·
+ 27.9%			

Historical Revenue (NZ\$m)	FY18	FY19	FY20
Group	2.4	1.8	38.3


EBITDA (Operating) - Total	20.6	(2.4)	944.5%
Margin (%)	53.8%	(137.3)%	

- **Group Revenue: NZ\$38.3m** (+2,056.8% vs. FY19)
- **Group Operating EBITDA: NZ\$20.6m** (+944.5% vs. FY19)
- **NPAT: NZ\$16.7m** (+788.7% vs. FY19)
- EPS (NZ\$): 10.20 cents per share (FY19 (1.48) cents per share))
- Dividend (NZ\$): 3.2 cents per share (31.5% NPAT payout ratio)
- Net assets: \$21.0m (sufficient balance sheet capacity to fund organic growth)

1.2 Business Highlights – Financial Performance








- Total Revenue: \$38,329,369
- Cost of Sales: \$9,995,761
- Other Revenue: \$170,778
- Operating Expenses: \$8,092,337
- Net Profit Before Tax: \$20,412,049

Financial Performance 30 June 2019 NZ\$




- Total Revenue: \$1,777,156
- Cost of Sales: \$960,463
- Other Revenue: \$136,142
- Operating Expenses: \$3,371,819
- Net Loss Before Tax: \$(2,418,984)

1.3 Business Highlights – Total Revenue

ZOONO®






1.4 Business Highlights – Revenue by Quarter


ZOONO®





1.5 Business Highlights – Gross Profit











Net Profit / (Loss) Before Tax NZ\$











Zoono Group Limited

#02

Financial Information



















2.1 Financial Summary – Consolidated Group Profit & Loss



Consolidated Group FY20 EBITDA (Operating): NZ\$20.6m (+944.5% vs. FY19)

Revenue (Group)

 Total Revenue: NZ\$38.3m (FY19: NZD\$1.8m) + NZ\$36.5m improvement
 +2,056.8% increase vs. FY19

EBITDA (Group)

 Operating EBITDA: NZ\$20.6m (FY19: NZ\$(2.4m)) + NZ\$23.0m improvement +944.5% increase vs. FY19

Consolidated Profit & Loss (NZ\$m)	Actual FY20	Actual 2019	FY20 vs. FY19 %
Revenue			
Revenue - Total	38.3	1.8	2,056.8%
Gross Profit	28.3	0.8	3,369.3%
Margin (%)	73.9%	46.0%	
+ 27.9%			
improvement			

EBITDA

Historical Revenue (NZ\$m)	FY18	FY19	FY20
Group	2.4	1.8	38.3

1	EBITDA (Operating) - Total	20.6	(2.4)	944.5%
	Margin (%)	53.8%	(137.3)%	

2.2 Financial Summary - Consolidated Balance Sheet

ZOONO

Strong balance sheet - sufficient capacity to fund growth

Balance Sheet (30 June-20)

- Net assets: NZ\$21.0m (FY19: \$3.8m) + NZ\$17.2m improvement
- Net cash: NZ\$10.3m (FY19: \$3.0m) + NZ\$7.3m improvement
 - Gross cash: NZ\$10.3m (FY19:\$3.1m) + NZ\$7.2m improvement

Capital Efficiency Metrics

- ROA: 48.0% (FY19 (51.5)%
- ROE: 79.5% (FY19 (62.8)%
- NTA: NZ\$20.9m (FY19 NZ\$ 3.8m)
- NTA per Share (NZ\$): 12.81 cents per share (FY19 2.32 cents per share)
- EPS (NZ\$): 10.20 cents per share (+789.2% vs. FY19)
- EPS (NZ\$ diluted): 10.13 cents per share (+784.5% vs. FY19)

Jun-20	Jun-19
16.7	(2.4)
163.3	163.1
164.4	163.1
	16.7 163.3

Earnings Per Share Diluted	10.13 cents	(1.48) cents
Earnings Per Share	10.20 cents	(1.48) cents

Balance Sheet (NZ\$m)	Actual Jun-20	Actual Jun-19
Total Assets	34.7	4.7
Net Assets	21.0	3.8
Cash	10.3	3.1
Debt (3rd Party)	0.0	(0.1)
Net Cash / (Debt)	10.3	3.0

Capital Efficiency Metrics (NZ\$m)	Actual Jun-20	Actual Jun-19
Return on Assets (ROA)		
NPAT Attributable to Shareholders Total Assets	16.7 34.7	(2.4) 4.7
Return on Equity (ROE)		
NPAT Attributable to Shareholders Shareholder Funds	16.7 21.0	(2.4) 3.8
Net Tangible Assets (NTA)		
Total Assets	34.7	4.7
Intangible Assets Total Liabilities	0.04 13.7	0.07 0.8
Net Tangible Asset per Share (NTA per Share)		
Total Assets	34.7	4.7
Intangible Assets Total Liabilities	0.04 13.7	0.07 0.8
Weighted Average Ordinary Shares (m's)	163.3	163.1



2.3 Financial Summary – Cash Flow & Working Capital Generating large cash reserves with high margins and low capital investment

Working Capital 30 June-20

- Working capital is actively managed with strong focus on cash flow.
- Huge investment in inventory of NZ\$13.2m reduced cash resources at year end.
- Majority of customers are 50% cash upfront on placing orders and 50% prior to delivery with terms for the rest.
- Low capital intensive business, despite investing in a concentrate plant in the USA (US\$170k), which will place less reliance on suppliers.

Dividend 30 June-20

(NZ\$) 3.2 cents per share

Record date of Dividend: 7 September 2020

Dividend payment date: 21 September 2020

Cash inflow /(outflow) from Operating Activities	Actual	Actual
(NZ\$m)	Jun-20	Jun-19
Net cash provided / (used in) operating activities	8.1	(2.9)
Cash outflow from Investing Activities	Actual	Actual
(NZ\$m)	Jun-20	Jun-19
Net cash used in investing activities	(0.13)	(0.034)
Cash inflow / (outflow) from Financing	Actual	Actual
Activities		
(NZ\$m)	Jun-20	Jun-19
	Jun-20 (0.20)	Jun-19 (0.027)
(NZ\$m) Net cash provided / (used in) financing	V	
(NZ\$m) Net cash provided / (used in) financing activities Net increase / (decrease) in cash and cash	(0.20)	(0.027)
(NZ\$m) Net cash provided / (used in) financing activities Net increase / (decrease) in cash and cash equivalents held	(0.20) 7.8	(0.027) (2.9)

2.4 Key Metrics – Revenues FY20

Group Revenue	S	
B2B B2C Animal Health	NZ\$30.4m NZ\$ 5.7m NZ\$ 2.2m	79% 15% 6%
Total	NZ\$38.3m	100%
Geographical R	evenues: Australa	asia, Asia, China, India, North America
B2B	NZ\$20.1m	75%
B2C	NZ\$ 5.1m	19%
Animal Health	NZ\$ 1.7m	6%
Total	NZ\$26.9m	100%

2.5 Key Metrics – Revenues FY20

Geographical Revenues: UK & Europe				
B2B B2C Animal Health	NZ\$10.3m NZ\$ 0.6m NZ\$ 0.5m	91% 5% 4%		
Total	NZ\$11.4m	100%		

2.6 Key Metrics – B2C FY20



B2C Average order size: Australasia, Asia, China, India, North America:

• Revenue: NZ\$5.1m

Average Order Size: NZ\$145

• Orders: 35,172

• Units Sold: 184,641

Avg. Units / Order 5.25

B2C Average order size: UK & Europe:

• Revenue: NZ\$0.61m

Average Order Size: NZ\$89

• Orders: 6,827

• Units Sold: 14,694

Avg. Units / Order 2.15

Zoono Group Limited

#03

Strategy & Growth

3.1 Strategy & Growth

Domestic & international organic expansion & positive outlook

B2B

- Continue to partner with global & national organisations that have existing customers, sales teams and distribution channels in place (locally and globally) to accelerate growth this year.
- Having control of the US market will accelerate growth in this area with sourcing new distributors.

Animal Health

- New regulatory approvals in countries being sought focussing on the pig / poultry industries.
- Big opportunity for Zoono to become a profit centre for farmers with improved food conversion ratios. We expect significant growth in this area.
- Field studies on poultry and pig farms undertaken in NZ, Australia, US, Portugal & Hungary have had outstanding results.

B₂C

- Invest more heavily in the UK & Europe which has tremendous upside.
- Having control of the US market will accelerate growth in this area with the marketing activities we have underway.
- Develop new markets via new products (face masks) with new innovative, marketing strategies.

New Sites

- Moving the US operation to new offices/warehouse as we look to grow the market significantly.
- New operation set up in Shanghai to further penetrate the Chinese market and develop new distributors.
- New operation set up in the Middle East to accelerate the growth already occurring.

3.2 Strategy & Growth

Domestic & international organic expansion & positive outlook

Quality & Service

- Continued testing.
- Improving products.
- Improving customer service.

Zoono Group Limited

Appendices

Appendix 1: Financial Reconciliation to Statutory Results



Reconciliation (NZ\$m)				
Revenue				
Cost of sales				
COST OF SUICS				
Gross profit				
percentage to revenue				
Other revenue				
Administration expenses				
Depreciation / Amortisation expenses				
Directors' fee				
Employee cost				
Finance cost				
Management fee				
Professional fees				
Share Based Payment				
Occupancy expenses				
Selling and distribution expenses				
Marketing expenses				
Listing expenses and other acquisition costs				
Other costs				
Profit / (Loss) before Income Tax				
percentage to revenue				
Income tax expense				
Profit / (Loss) attributable to members				
Exchange differences on translation of foreign operations				
Total comprehensive profit / (loss) attributable to members				
percentage to revenue				

FY20 30 Jun-20				
1H20 (A)	2H20 (A)	FY20 (A)		
1.715	36.614	38.329		
(0.822)	(9.174)	(9.996)		
0.893	27.440	28.333		
52.1%	74.9%	73.9%		
0.054	0.117	0.171		
(0.019)	(0.083)	(0.102)		
(0.019)	(0.083)	(0.102)		
(0.064)	(0.066)	(0.130)		
(0.409)	(1.770)	(2.179)		
(0.018)	(0.035)	(0.053)		
(0.189)	(0.241)	(0.430)		
(0.261)	(0.837)	(1.098)		
(0.069)	(0.297)	(0.366)		
(0.021)	(0.021)	(0.042)		
(0.235)	(1.513)	(1.748)		
(0.116)	(0.152)	(0.268)		
(0.060)	(0.146)	(0.206)		
(0.139)	(1.134)	(1.273)		
(0.728)	21.140	20.412		
(42.4%)	57.7%	53.2%		
0.000	(3.753)	(3.753)		
(0.728)	17.387	16.659		
0.005	(0.543)	(0.538)		
(0.723)	16.844	16.121		
(42.4%)	46.0%	42.1%		

Zoono has not audited or investigated the accuracy or completeness of the information, statements and opinions contained in this presentation. Whilst provided in good faith, to the maximum extent permitted by applicable laws, Zoono makes no representation and can give no assurance, guarantee or warranty, express or implied, as to, and takes no responsibility and assumes no liability for (1) the authenticity, validity, accuracy, suitability or completeness of, or any errors in or omission from, any information, statement or opinion contained in this presentation and (2) without prejudice to the generality of the foregoing, the achievement or accuracy of any forecasts, projections or other forward looking information contained or referred to in this presentation.

This overview of the Company does not purport to be all inclusive or to contain all information which its recipients may require in order to make an informed assessment of Zoono's prospects. You should conduct your own investigation and perform your own analysis in order to satisfy yourself as to the accuracy and completeness of the information, statements and opinions contained in this presentation before making any investment decision.

Future Performance

This presentation contains forecasts, projections and forward looking information. Such forecasts, projections and information are not a guarantee of future performance and involve unknown risks and uncertainties, many of which are out of Zoono's control. Actual results and developments will almost certainly differ materially from those expressed or implied.

Zoono disclaims any intent or obligation to update publicly any forward-looking statements, whether as a result of new information, future events or results or otherwise. The words "believe", "expect", "anticipate", "indicate", "contemplate", "target", "plan", "intends", "continue", "budget", "estimate", "may", "will", "schedule" and other similar expressions identify forward-looking statements. All forward-looking statements made in this presentation are qualified by the foregoing cautionary statements. Investors are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.



NZ +64 9 600 1188

zoono.com | Zoon Group Limited (ASX:ZNO)